# Autologous Fat Grafting Combined With Platelet-Rich Plasma in the Treatment of Female Genitourinary Aging: A Retrospective Study

**Authors:** Qing-Xian Ren, Kai-Zi Li, Guo-Liang Shen, Chun-Hui Huang

PMC · DOI: 10.1093/asjof/ojaf165 · 2025-12-13

## TL;DR

This study shows that combining fat grafting and platelet-rich plasma can safely improve genital appearance and sexual function in women with aging-related issues.

## Contribution

The study presents new clinical evidence for the combined use of AFG and PRP in treating female genitourinary aging.

## Key findings

- VLQ scores improved significantly after treatment, indicating better vaginal tightness.
- 92.1% of patients reported high satisfaction with appearance and tightness.
- Sexual function scores (FSFI) improved across all dimensions, with minimal complications.

## Abstract

Female genitourinary aging (because of childbirth, menopause, weight changes, and aging) causes genital shrinking, vaginal laxity, dyspareunia, and urinary issues, impairing quality of life. Current treatments (lubricants, hormone creams, and laser) are temporary, have drawbacks, or lack clear guidelines. Autologous fat grafting (AFG) enables safe volumization, and platelet-rich plasma (PRP) promotes tissue repair, but evidence for their combination here is scarce.

The aim of this study was to explore the clinical efficacy and safety of AFG combined with PRP in female external genitalia and vaginal rejuvenation.

A retrospective study included 38 patients (January 2020 to December 2024) with genital/vaginal aging who received combined AFG (mons pubis, labia majora, G-spot, and perineum) and PRP. Postoperative evaluations were performed with the Vaginal Laxity Questionnaire (VLQ) and the Female Sexual Function Index (FSFI), and complication monitoring was conducted.

Postoperative VLQ scores rose from 2.45 ± 0.81 to 5.03 ± 1.15 (P = .027). All 6 dimensions of the FSFI (sexual interest, sexual arousal, vaginal lubrication, orgasm, sexual satisfaction, and dyspareunia) and the total FSFI score also significantly improved (all P < .05), with a mean total FSFI increase of 9.0 ± 2.3 points (a ≥4-point increase is clinically meaningful); 92.1% (35/38) were “very satisfied” with appearance/tightness. Only 2 (5.3%) experienced mild redness (resolved with oral antibiotics); no severe complications occurred.

In this small cohort with limited follow-up, AFG combined with PRP treatment appears to improve the external appearance of female external genitalia and vaginal aging and enhance genital function, improve patient-reported sexual function (based on FSFI) and reduce urinary system problems.

4 (Therapeutic)

## Full-text entities

- **Genes:** F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}
- **Diseases:** urinary leaks (MESH:D019559), depression (MESH:D003866), orgasmic dysfunction (MESH:D020018), hormone (MESH:C565870), immune system diseases (MESH:D007154), swelling (MESH:D004487), coronary heart disease (MESH:D003327), Laxity (MESH:D007593), positive (MESH:D000377), AFG (MESH:D004620), atrophic vaginitis (MESH:D059268), allergic reactions (MESH:D004342), atrophy of the mons pubis and labia majora (MESH:C567360), volume deficiency (MESH:D007153), breast cancer (MESH:D001943), itching (MESH:D011537), inflammation (MESH:D007249), stress urinary incontinence (MESH:D014550), stroke (MESH:D020521), hematological diseases (MESH:D006402), mental illnesses (MESH:D001523), Vaginal Laxity (MESH:D014627), depressed scars (MESH:D002921), skin ulcers (MESH:D012883), dyspareunia (MESH:D004414), Raynaud's phenomenon (MESH:D011928), fibrosis (MESH:D005355), coagulation dysfunction (MESH:D001778), cancer (MESH:D009369), sexual dysfunction (MESH:D012735), GSM (MESH:D014564), volume loss (MESH:D016388), urinary issues (MESH:D014548), dryness (MESH:D014987), systemic sclerosis (MESH:D012595), venous thromboembolism (MESH:D054556), atrophy (MESH:D001284), sun (MESH:D013474)
- **Chemicals:** calcium chloride (MESH:D002122), testosterone (MESH:D013739), sodium bicarbonate (MESH:D017693), cefuroxime (MESH:D002444), carbon dioxide (MESH:D002245), water (MESH:D014867), oil (MESH:D009821), vitamin E (MESH:D014810), lidocaine (MESH:D008012), epinephrine (MESH:D004837), AFG (-), dexamethasone (MESH:D003907), sodium citrate (MESH:D000077559)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12813633/full.md

---
Source: https://tomesphere.com/paper/PMC12813633